<div id="readability-page-1"><p>Assenagon Asset Management S.A. reduced its position in shares of  Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 96.6% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor  owned 29,482 shares of the biotechnology company's stock after selling 838,457 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Sarepta Therapeutics were worth $568,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Sarepta Therapeutics</strong> alerts:</span></p></div><ul><li>Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside</li></ul><p>Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Ancora Advisors LLC increased its position in shares of  Sarepta Therapeutics by 150.0% during the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 300 shares in the last quarter.  Banque Transatlantique SA purchased a new stake in  Sarepta Therapeutics during the 1st quarter valued at $44,000.  AlphaQuest LLC bought a new stake in shares of  Sarepta Therapeutics in the 1st quarter worth $141,000.  GAMMA Investing LLC increased its holdings in shares of  Sarepta Therapeutics by 285.6% in the 3rd quarter. GAMMA Investing LLC now owns 3,089 shares of the biotechnology company's stock worth $60,000 after purchasing an additional 2,288 shares in the last quarter.  Finally, Blue Trust Inc. raised its stake in shares of  Sarepta Therapeutics by 542.3% in the second quarter. Blue Trust Inc. now owns 3,282 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 2,771 shares during the last quarter. Institutional investors own  86.68% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>Several equities research analysts recently commented on SRPT shares. Wells Fargo &amp; Company reduced their price objective on Sarepta Therapeutics from $50.00 to $45.00 and set an &#34;overweight&#34; rating for the company in a report on Wednesday, November 5th. Robert W. Baird reduced their price target on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a &#34;neutral&#34; rating for the company in a research note on Tuesday, November 4th. Weiss Ratings  restated a &#34;sell (d)&#34; rating on shares of Sarepta Therapeutics in a research report on Monday. Bank of America lifted their target price on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock an &#34;underperform&#34; rating in a research report on Wednesday, October 22nd. Finally, Leerink Partners boosted their target price on shares of Sarepta Therapeutics from $12.00 to $15.00 and gave the company a &#34;market perform&#34; rating in a research note on Tuesday, September 9th. Nine analysts have rated the stock with a Buy rating, fifteen have issued  a Hold rating and six have assigned  a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $33.68.</p><ul><li>Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences</li></ul><p><b>Get Our Latest Stock Analysis on Sarepta Therapeutics</b></p><h2>Insiders Place Their Bets</h2><p>In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total transaction of $294,201.97. Following the completion of the sale, the chief operating officer directly owned 193,300 shares of the company's stock, valued at $4,312,523. This trade represents a 6.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 7.60% of the stock is owned by insiders. </p><h2>Sarepta Therapeutics Trading Up 1.3%</h2><ul><li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li></ul><p>Shares of Sarepta Therapeutics stock opened at $22.29 on Friday. Sarepta Therapeutics, Inc. has a fifty-two week low of $10.41 and a fifty-two week high of $129.84. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 2.95. The company has a market capitalization of $2.34 billion, a P/E ratio of -7.41 and a beta of 0.54. The company has a fifty day moving average of $20.74 and a 200 day moving average of $20.02. </p><p>Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.15). The business had revenue of $399.36 million during the quarter, compared to analysts' expectations of $331.51 million. Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. Sarepta Therapeutics's revenue was down 14.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.62 earnings per share.  On average, sell-side analysts anticipate that  Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year. </p><h2>Sarepta Therapeutics Profile</h2> (Free Report)<p>Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.  </p><p>Sarepta's commercial products include several exon-skipping therapies approved by the U.S.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Sarepta Therapeutics</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li><li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li><li>Washington prepares for war</li><li>Strange Crystal Metal Outperforms Silicon Up to 100X</li><li>33,000% boom from weird new “AI Fuel?”</li></ul><p><strong>Want to see what other hedge funds are holding SRPT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Sarepta Therapeutics Right Now?</h2><p>Before you consider Sarepta Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.</p><p>While Sarepta Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SRPT

<p>Assenagon Asset Management S.A. significantly reduced its stake in Sarepta Therapeutics, Inc. by 96.6% in the third quarter, selling 838,457 shares. The remaining 29,482 shares are valued at $568,000. Several other institutional investors have adjusted their positions in the company. Analysts have mixed ratings on Sarepta, with a consensus rating of 'Hold' and a target price of $33.68. Sarepta's stock opened at $22.29, with a market cap of $2.34 billion.</p>

Assenagon Asset Management S.A. Sells 838,457 Shares of Sarepta Therapeutics, Inc. $SRPT